238 related articles for article (PubMed ID: 2086492)
1. On brain protection of co-dergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies.
Saletu B; Grünberger J; Anderer R
Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):510-24. PubMed ID: 2086492
[TBL] [Abstract][Full Text] [Related]
2. Dose-response studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry.
Saletu B; Grünberger J; Linzmayer L; Anderer P
Psychopharmacology (Berl); 1992; 109(1-2):30-40. PubMed ID: 1365669
[TBL] [Abstract][Full Text] [Related]
3. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: II. Double-blind, placebo-controlled EEG mapping and psychometric studies under hypoxia.
Saletu B; Grünberger J; Anderer P; Linzmayer L
Methods Find Exp Clin Pharmacol; 1996; 18(1):67-81. PubMed ID: 8721258
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man.
Saletu B; Hitzenberger G; Grünberger J; Anderer P; Zyhlarz G; Linzmayer L; Rameis H
Int J Clin Pharmacol Ther; 1995 May; 33(5):249-62. PubMed ID: 7655763
[TBL] [Abstract][Full Text] [Related]
5. On the cerebro-protective effects of caroverine, a calcium-channel blocker and antiglutamatergic drug: double-blind, placebo-controlled, EEG mapping and psychometric studies under hypoxia.
Saletu B; Grünberger J; Anderer P; Linzmayer L; König P
Br J Clin Pharmacol; 1996 Feb; 41(2):89-99. PubMed ID: 8838434
[TBL] [Abstract][Full Text] [Related]
6. Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry.
Saletu B; Grünberger J; Linzmayer L; Anderer P
J Neural Transm Park Dis Dement Sect; 1990; 2(4):305-25. PubMed ID: 2127674
[TBL] [Abstract][Full Text] [Related]
7. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies.
Saletu B; Schulz H; Herrmann WM; Anderer P; Shrotriya RC; Vanbrabant E
Pharmacopsychiatry; 1994 Sep; 27(5):189-97. PubMed ID: 7838889
[TBL] [Abstract][Full Text] [Related]
8. Effect-kinetics on brain protection of two codergocrine-mesylate preparations (Aramexe retard and Hydergine) by EEG mapping and psychometry under hypoxia.
Saletu B; Grünberger J; Anderer P; Linzmayer L; Pakesch G; Zyhlarz G
Arch Gerontol Geriatr; 1994; 18(2):81-99. PubMed ID: 15374302
[TBL] [Abstract][Full Text] [Related]
9. The hypoxia model in human psychopharmacology: neurophysiological and psychometric studies with aniracetam i.v.
Saletu B; Grünberger J
Hum Neurobiol; 1984; 3(3):171-81. PubMed ID: 6434496
[TBL] [Abstract][Full Text] [Related]
10. Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration.
Saletu B; Grünberger J; Anderer P; Linzmayer L; König P
Arzneimittelforschung; 1995 Mar; 45(3):217-29. PubMed ID: 7741773
[TBL] [Abstract][Full Text] [Related]
11. Psychophysiological research in psychiatry and neuropsychopharmacology. II. The investigation of antihypoxidotic/nootropic drugs (tenilsetam and co-dergocrine-mesylate) in elderlies with the Viennese Psychophysiological Test-System (VPTS).
Saletu B; Semlitsch HV; Anderer P; Resch F; Presslich O; Schuster P
Methods Find Exp Clin Pharmacol; 1989 Jan; 11(1):43-55. PubMed ID: 2716439
[TBL] [Abstract][Full Text] [Related]
12. On the central effects of a new partial benzodiazepine agonist Ro 16-6028 in man: pharmaco-EEG and psychometric studies.
Saletu B; Grünberger J; Linzmayer L
Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):51-65. PubMed ID: 2921096
[TBL] [Abstract][Full Text] [Related]
13. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia.
Saletu B; Grünberger J; Anderer P; Linzmayer L
Methods Find Exp Clin Pharmacol; 1996; 18(1):55-66. PubMed ID: 8721257
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry.
Arnold O; Saletu B; Anderer P; Assandri A; di Padova C; Corrado M; Saletu-Zyhlarz GM
Eur Neuropsychopharmacol; 2005 Oct; 15(5):533-43. PubMed ID: 16046102
[TBL] [Abstract][Full Text] [Related]
15. Acute and subacute CNS effects of milacemide in elderly people: double-blind, placebo-controlled quantitative EEG and psychometric investigations.
Saletu B; Grünberger J; Linzmayer L
Arch Gerontol Geriatr; 1986 Oct; 5(3):165-81. PubMed ID: 3541816
[TBL] [Abstract][Full Text] [Related]
16. EEG brain mapping and psychometry in age-associated memory impairment after acute and 2-week infusions with the hemoderivative Actovegin: double-blind, placebo-controlled trials.
Saletu B; Grünberger J; Linzmayer L; Anderer P; Semlitsch HV
Neuropsychobiology; 1990-1991; 24(3):135-48. PubMed ID: 2135068
[TBL] [Abstract][Full Text] [Related]
17. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.
Saletu B; Grünberger J; Linzmayer L; Anderer P
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):12-27. PubMed ID: 2883677
[TBL] [Abstract][Full Text] [Related]
18. Encephalotropic and psychotropic effects of intravenous buflomedil in the elderly: double-blind, placebo-controlled pharmaco-EEG and psychometric studies.
Saletu B; Grünberger J; Linzmayer L; Stöhr H
Int J Clin Pharmacol Res; 1984; 4(2):95-107. PubMed ID: 6469443
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial.
Arrigo A; Casale R; Giorgi I; Guarnaschelli C; Zelaschi F
Curr Med Res Opin; 1989; 11(8):491-500. PubMed ID: 2680286
[TBL] [Abstract][Full Text] [Related]
20. [Potentiation by carbon dioxide of carbon monoxide-induced death in the hypoxic condition].
Harafuji K
Nihon Hoigaku Zasshi; 1992 Jun; 46(3):198-211. PubMed ID: 1405013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
